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Growth control: Invertebrate insulin surprises!
Sally J. Leevers
Recent work on Drosophila has provided new insights
into how insulin signalling — conserved in mammals,
flies and worms — regulates growth and cell division
during development. Invertebrates have been found to
possess more insulin-like ligands than predicted, some
of which behave as receptor antagonists.
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Intercellular communication is essential for multicellular
organisms to coordinate their development and complex
physiological functions. When this communication occurs at
a distance, extracellular ligands are employed to relay mes-
sages from one cell type to another that displays ligand-spe-
cific transmembrane receptors. Once the ligand is bound,
a conformational change is transmitted to the intracellular
domains of the receptor molecules, activating signalling
cascades and, ultimately, altering cell behaviour. One such
means of intercellular communication that has been studied
in depth is the mammalian insulin signalling pathway.
Impaired insulin signalling in humans results in type II
diabetes — a complex physiological disorder characterised
by defective nutrient uptake and metabolism. Consistent
with the complex nature of diabetes, insulin signalling
influences numerous processes, including glucose uptake,
metabolism, protein synthesis, growth and cell division.
The insulin receptor is a tetramer of two extracellular
alpha subunits, linked by disulphide bonds to two beta
subunits, which traverse the cell membrane and have
intracellular tyrosine kinase domains. When insulin binds,
the tyrosine kinase domains of the receptor undergo
transphosphorylation, resulting in autoactivation and trigger
a signalling cascade initiated by the lipid kinase phos-
phatidylinositol 3-kinase (PI 3-kinase) and including
several serine/threonine kinases.
This signalling pathway, from the receptor to the target
serine/threonine kinases, is conserved through evolu-
tion, and has been characterised extensively in the fruit-
fly Drosophila and the nematode worm Caenorhabditis
elegans. Recent studies [1–4] of insulin signalling in
invertebrates have provided new insights into its role in
growth regulation [1], and also some surprises. Firstly,
both flies and worms have been found to possess many
more insulin-like ligands than expected [1–4]; and sec-
ondly, data from worms suggest that some insulin-
like ligands antagonise, rather than activate, the insulin
signalling pathway [2].
Growth regulation by insulin signalling in Drosophila
During development, the regulation of growth — mass
increase — and cell division generates animals of consis-
tent size, containing cells of constant size and number [5].
In Drosophila, the insulin signalling pathway regulates the
growth of larval imaginal discs [6–8]. These epithelial
bilayers are reorganised during metamorphosis to con-
struct the adult epidermis; when insulin signalling is
reduced, disc growth, disc size and also adult fly size are
decreased. Detailed analyses in the imaginal discs have
shown that reducing insulin signalling reduces both the
size and number of cells. In contrast, when the activity of
the pathway is artificially enhanced (by transgene expres-
sion), growth and cell size are increased, but cell number
does not increase significantly. This observation suggests
that activation of the pathway may not be sufficient to
trigger cell division [8].
So far, studies of growth regulation in Drosophila have
focussed on what happens when the activity of PI 3-kinase
and downstream serine/threonine kinases is altered.
Although certain mutant combinations of the Drosophila
insulin receptor (DInr) have been reported to produce
small flies [9,10], this phenotype has, until recently, not
been analysed at the cellular level. This has changed with
the experiments reported in a recent issue of Current
Biology by Brogiolo et al. [1], who have examined the
function of the DInr more closely. They have found that
overexpression of DInr in Drosophila leads to an increase
in growth, cell size and also cell number. 
Brogiolo et al. [1] generated transgenic Drosophila in which
DInr was overexpressed in the proliferating cells of
the developing eye. They found that this resulted in the
production of dramatic outgrowths, and eyes containing
more, as well as larger, cells. This observation is important,
as it implies that the pathway may branch at the level of
the receptor, with a growth-promoting signal being trans-
duced via the PI 3-kinase pathway, and a cell-division-pro-
moting signal being transduced via a second signalling
pathway. The observation that mitogen activated protein
(MAP) kinase is activated in the heads of flies overex-
pressing activated DInr suggests that the Ras/MAP kinase
pathway might transduce this second signal [1]. It should
be noted, though, that overexpression of the DInr
increases growth more than it induces cell division, as it
still increases cell size.
Drosophila insulin-like pepides
The alpha chain of DInr shares sequence similarity with
mammalian insulin receptors, suggesting that DInr is
activated by insulin-like ligands [9,10]. Brogiolo et al. [1]
used homology searches of the Drosophila genome to
identify putative DInr ligands, referred to as DILPs for
‘Drosophila insulin-like peptides’ [1]. Given that the
Drosophila genome has just one insulin receptor homo-
logue, and fewer isoforms of the downstream signalling
components than mammals, it is surprising that seven
genes encoding DILPs were identified. These ligands
have a domain structure similar or identical to mammalian
insulin, including four consistently spaced cysteines within
the A-chain, and consensus cleavage sites allowing prote-
olysis to generate active A-chain:B-chain dimers. Their
amino acid sequences and domain structure are both more
like mammalian insulin than the insulin-like growth
factors, IGF1 and IGF2. 
Ubiquitous overexpression of DILP2 — the family
member that most closely resembles insulin — during disc
development produced large flies [1]. Several observations
suggest that DILP2 acts via DInr to increase growth.
Firstly, the DILP2-induced large flies have more cells as
well as larger cells. Secondly, mutation of one copy of dinr
suppressed the DILP2-induced formation of large flies.
And thirdly, the formation of large eyes by DInr overex-
pression was suppressed in flies heterozygous for a dele-
tion that removes the genes for DILP1–5, suggesting that
overexpressed DInr is dependent on the DILPs for its
activity. And finally, embryonic overexpression of DILP2
was lethal and could also be suppressed by reducing DInr
or downstream serine/threonine kinase activity. Given the
postulated bifurcation of signalling from DInr (see above),
it would be interesting to determine whether mutation of
genes on the Ras/MAP kinase pathway also suppresses the
DILP2-induced phenotypes.
As starvation during larval development also reduces
growth, resulting in small flies, and as nutrients induce
insulin secretion in mammals, it has been postulated
that signalling via the Drosophila insulin pathway is nutri-
ent-sensitive [6–8,11]. Furthermore, the larval fat body
has been proposed as a nutrient-sensitive tissue that
might secrete growth-promoting factors. But when the
expression patterns of dilp mRNAs were examined by
in situ hybridisation, no expression in the fat body was
observed [1]. Highly localised expression patterns were
observed, though. For instance, DILP2, DILP4 and
DILP7 are expressed in the embryonic mesoderm and
mid-gut; DILP2 is expressed at low levels in the imaginal
discs; and DILP2, DILP3 and DILP5 are expressed at
high levels in brain cells that may be neurosecretory
(Figure 1a). Brogiolo et al. [1] speculate that DILPs pro-
duced by these cells may be transported to the ring gland,
which contains the fly corpora cardiaca, then released from
the copora cardiaca in a nutrient-dependent manner.
It remains to be seen whether the transcription, expres-
sion and secretion of any or all of the dilp genes is nutri-
ent-sensitive, but we now have the tools to make this
possible. It will also be interesting to examine whether
the forced overexpression of DILPs in one tissue is suffi-
cient to drive the growth of another tissue, and if so, at
what distances the DILPs can act.
A conserved role for insulin signalling in growth regulation
These results emphasise the striking conservation of
insulin signalling function through evolution. Impaired
insulin signalling in humans is classically associated with
insulin resistance and type II diabetes, and can result
from mutation of the insulin receptor (as well as other
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Figure 1
Drosophila and C. elegans insulin
homologues have neuronal expression
patterns. (a) Several Drosophila insulin-like
peptides are expressed in the brain. For
example, in situ hybridisation reveals that
dilp3 is exclusively transcribed in seven cells
in each larval brain hemisphere (shown in
black), which may correspond to
neurosecretory cells; dilp2 and dilp5 are
transcribed in the same cells [1]. (b) Most of
the C. elegans insulin homolgues examined
are expressed in at least some amphid
sensory neurons. For example, fusion of green
fluorescent protein to the ins-1 promoter
reveals that ins-1 is expressed in various
neurons throughout the worm [2], including
the amphid sensory neurons ASI and ASJ,
which regulate dauer arrest [15].
molecules). In some clinical syndromes, however, increased
insulin secretion can increase growth, and insulin defi-
ciency can hinder growth. Furthermore, one human
patient has been identified with a homozygous mutation
in the insulin receptor that retards growth and reduces
body size, causing a syndrome known as leprechaunism
[12]. This observation provides compelling evidence that
an evolutionarily conserved function of insulin signalling
is the regulation of growth and body size.
C. elegans has 37 insulin-like ligands
Several C. elegans laboratories, like their colleagues working
on Drosophila, have taken a bioinformatics approach to
identifying putative ligands for the worm insulin receptor
homologue, DAF-2 [2–4]. Extensive searches, based on
sequence homology and structural predictions, have iden-
tified an insulin supergene family with a remarkable 37
genes: ins-1–ins-37. The ligands encoded by these genes
have been sub-classified into four types, according to their
predicted disulfide bond connectivity [2]. Of the resulting
four groups, the gamma type includes mammalian insulin
and IGFs, DILPs1–7 and eleven of the C. elegans ligands [2]. 
Why C. elegans should have so many insulin-like ligands is
at present unclear — as in Drosophila, only one putative
receptor has been identified. While functional redundancy
is a possibility, some experiments suggest distinct
functions for different ligands (see below). In addition,
fusion of various ins gene promoter and enhancer regions
to a reporter gene encoding green fluorescent protein
(GFP) revealed specific and distinct expression patterns,
consistent with the different genes being regulated by
distinct cues, in order to provide distinct functions
(Figure 1b) [2].
Insulin-like ligands as receptor antagonists in C. elegans
In C. elegans, insulin signalling regulates the formation of
dauer larvae — stress-resistant, metabolically inactive and
long-lived larvae, which normally form in response to
overcrowding and starvation. When DAF-2 or down-
stream pathway components are mutated, dauer formation
increases, even in the presence of food. Mutants which do
reach adulthood have significantly extended adult lifes-
pans, possibly because these adult worms have some
dauer-like characteristics [13]. Conversely, when negative
regulators of the pathway are mutated, the resulting worms
have a reduced ability to form dauers, even when starved
or crowded.
One approach to investigating ins gene function was to
delete part of the ins-1 gene. No effect on dauer formation
or adult lifespan was observed in wild type or daf-2 mutant
worms, suggesting that ins-1 function may be redundant
with another ins gene [2]. As an alternative approach,
worms were generated that overproduce INS molecules or
human insulin. It was predicted that, like mutation of
negative regulators of the DAF-2 pathway, the overpro-
duction of INS molecules would reduce dauer formation.
Instead, overproduction of INS-1 or INS-18 — the worm
ligands most like human insulin — or of human insulin
itself was found to enhance dauer formation, both in wild-
type worms and in daf-2 mutants, which already form
dauers at an increased frequency. Furthermore, INS-1
overproduction slightly extended adult lifespan [2].
These observations are surprising, as they imply that INS-
1, INS-18 and human insulin antagonise rather than
activate DAF-2 signalling. When INS-9, INS-19, INS-22
and INS-31 were overproduced, they did not affect dauer
formation. These ligands may be non-functional, or may
influence biological processes not examined in these
experiments. Other, as yet untested, INS peptides may
behave as expected — as activators of DAF-2 signalling.
But the ability of INS-1, INS-18 and human insulin to
antagonise DAF-2 signalling still has to be explained. Some
extracellular ligands activate their receptors at low concen-
trations, yet at high concentration, or after long-term treat-
ment, downregulate signalling from the same receptor. To
ensure that the apparent antagonism of DAF-2 signalling
was not a result of chronic ligand overexpression, the
transgene dosage was lowered [2]. The ability of INS-1 to
enhance daf-2 dauer formation persisted, even when only
twice the wild-type ins-1 gene dosage was used.
So it seems that at least some worm INS peptides
can antagonise DAF-2 signalling. How might this occur?
Human insulin, which certainly activates the human
insulin receptor, also antagonises DAF-2 signalling. This
finding suggests that the ability of INS-1 and INS-18 to
antagonise DAF-2 signalling may not be a peculiarity of
the ligands themselves, rather a consequence of what does
(or does not) happen when these ligands bind to DAF-2.
The structures of human insulin and the insulin receptor
have been analysed in remarkable detail, and recently the
three-dimensional structure of the entire receptor com-
plexed with insulin has been determined by electron
microscopy [14]. This information has provided molecular
insights into how insulin binding brings the intracellular
domains into sufficiently close proximity for transphos-
phorylation to occur. While it is possible that the structure
of DAF-2 has evolved to allow exactly the opposite, this is
hard to imagine! A more likely explanation is that the
antagonistic ligands bind but do not activate DAF-2, and
thereby compete with the true receptor agonists. Molecu-
lar modelling of the ligand and receptor domains and
residues involved in ligand–receptor interaction and
receptor activation process might prove informative here. 
Another possibility is that, instead of the antagonism
occurring at the level of the ligand–receptor interaction, it
occurs further upstream. INS-1, INS-18 and human
insulin might interact non-productively with molecules
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involved in ligand processing and secretion, or with
molecules homologous to the mammalian IGF-binding pro-
teins that modulate ligand–receptor interactions. Whether
such interactions occur only when the ligands are over-
produced, or whether they reflect the true functions of
INS-1 and INS-18 remains to be seen. It should also be
noted that it has not been proven that any of the worm or
fly insulins do actually bind to their assumed receptors.
Simple biochemical analyses to examine whether INS-1
and INS-18 do bind and activate or inactivate DAF-2 will
be useful. In addition, more extensive mutation of the
worm ins genes should provide a more complete view of
their function.
These analyses of insulin-like protein function in inverte-
brates have important implications for human insulin sig-
nalling. Firstly, might more extensive bioinformatic analysis
of the human genome, using the techniques applied in
C. elegans and Drosophila, identify more insulin-like mole-
cules? And, secondly, if these molecules exist, might some
of them act by antagonising, as opposed to activating,
insulin signalling?
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